Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?

Abstract

Introduction: Hepatitis B virus (HBV) reactivation after ‘resolved’ infection can occur in the setting of immunosuppression, including iatrogenically induced by anti-CD20 antibodies. The presence of antibodies against the HBV core antigen (anti-HBc) is a marker of risk for this phenomenon. The risk of this occurring in patients with circulating HBV surface antigen (HBsAg) is well characterized, but is less well characterized in patients who are HBsAg negative.

Areas covered: This article reviews the literature regarding HBV reactivation in the context of rituximab therapy. We have limited our review to HBsAg-negative patients, and clinical outcomes following HBV reactivation.

Expert opinion: We have recommended prophylactic anti-viral therapy for all HBsAg-negative/anti-HBc-positive patients undergoing rituximab therapy in combination with other immunosuppressive therapy.

Keywords:

• anti-hepatitis B virus core antigen
• CD20 monoclonal antibodies
• chemotherapy
• hepatitis B virus surface antigen negative/anti-HBc positive
• hepatitis B virus
• immunosuppression
• reactivation of hepatitis B virus
• retuximab

Declaration of interest

HW Hann received research grants from Bristol-Myers Squibb and Gilead Science. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.

Notes

This box summarizes key points contained in the article.